About us | 메디노

To offer the most valuable

treatment of
neurological diseases

The number of patients suffering from degenerative brain diseases such as stroke and Alzheimer's disease is rapidly increasing as major countries in the world, including South Korea, enter into ultra-aging stage. In addition, the incidence of neonatal brain diseases is also rapidly going up since increase in women's age at first birth makes the birth rate of premature babies grow.

Medinno Inc. has been striving to develop cell therapeutics for brain diseases for over 15 years to give hope to numerous patients and families suffering from brain diseases.

: As a result of repeated scientific studies on the efficacy and safety of cell therapeutics, it’s convinced that Medinno Inc.'s cells now could be applied to patients with brain diseases range from neonatal brain diseases such as hypoxic ischemic encephalopathy (HIE) and intraventricular hemorrhage (IVH) to adult brain diseases such as spinal cord injury (SCI) and stroke. Based on the cell therapy technologies that has been developed for a long time, Medinno Inc. is currently performing many preclinical researches and clinical trials of cell therapy treatments for various brain diseases.

Vision

Innovation
To be the most innovative biomedical company with world best technologies
Creation
To make novel stem cell therapeutics and expand the horizon of interventions
Hope
To make patients with brain diseases and their families have hope

Medinno Inc.

Intends to equip cell therapy products that can treat brain diseases throughout the entire cycle of a person from newborn to old age. All of our employees will do our best to help patients with brain diseases recover with the cell therapy we developed. Medinno Inc. will develop into a cell therapy company specializing in brain diseases with world-class technologies.